![Carlos Paya](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Carlos Paya
Presidente presso
VAXCYTE, INC.
Patrimonio netto: 725 521 $ in data 30/06/2026
Profilo
Carlos V.
Paya is currently Chairman at Vaxcyte, Inc. since 2021, Executive Chairman at Highlight Therapeutics SL since 2020, Director at Collegium Pharmaceutical, Inc. starting 2025, Director at Mallinckrodt Pharmaceuticals Ltd., Venture Partner at Abingworth Management, Inc. since 2020, and Venture Partner at Ysios Capital Partners SGEIC SA since 2020.
Former positions include President, Chief Executive Officer & Director at Immune Design Corp.
from 2011 to 2019, Chairman at Standard BioTools, Inc. from 2020 to 2024, Independent Director at Keenova Therapeutics Plc from 2019 to 2022, President at Elan Corp.
Plc and Elan Pharmaceuticals LLC from 2008 to 2011, Vice President at Lilly Research Laboratories from 2001 to 2008, Professor-Medicine, Immunology & Pathology at Mayo Medical School from 1991 to 2011, and Global Head-Diabetes at Eli Lilly & Co. Education includes a doctorate from Universidad Complutense de Madrid.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
VAXCYTE, INC. 0,01% | 15/06/2026 | 12.481 ( 0,01% ) | 725 521 $ | 30/06/2026 |
| 14/05/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Posizioni attive di Carlos Paya
| Società | Posizione | Inizio |
|---|---|---|
| VAXCYTE, INC. | Presidente | 27/10/2021 |
| COLLEGIUM PHARMACEUTICAL, INC. | Direttore/Membro del Consiglio | 15/05/2025 |
Highlight Therapeutics SL
 Highlight Therapeutics SL BiotechnologyHealth Technology Develops immuno-oncology treatments for skin cancers | Presidente | 17/04/2020 |
Mallinckrodt Pharmaceuticals Ltd.
 Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Direttore/Membro del Consiglio | - |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital invests in companies located across the globe. The firm targets companies operating in the fields of the biotechnology sector. It provides financing for early and growth stage capital requirements. | Investitore di Private Equity | 01/06/2020 |
Abingworth Management, Inc.
 Abingworth Management, Inc. Investment ManagersFinance Acts as an alternative investment manager | Consulente / Consigliere | - |
Precedenti posizioni note di Carlos Paya
| Società | Posizione | Fine |
|---|---|---|
| STANDARD BIOTOOLS INC. | Presidente | 05/01/2024 |
| MALLINCKRODT PLC | Direttore/Membro del Consiglio | 16/06/2022 |
| IMMUNE DESIGN CORP | Amministratore Delegato | 02/04/2019 |
| ░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Carlos Paya
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
73
Relazioni di 1° grado
15
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 15 |
|---|---|
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals and drug delivery systems | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Standard BioTools, Inc.
 Standard BioTools, Inc. Medical SpecialtiesHealth Technology Manufactures and markets innovative technologies and tools for life sciences research | Health Technology |
Collegium Pharmaceutical, Inc.
 Collegium Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Elan Pharmaceuticals LLC
 Elan Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Keenova Therapeutics Plc
 Keenova Therapeutics Plc BiotechnologyHealth Technology Develops therapeutics for rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology and neonatal respiratory problems | Health Technology |
Universidad Complutense de Madrid
 Universidad Complutense de Madrid Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Abingworth Management, Inc.
Abingworth Management, Inc. Investment ManagersFinance Acts as an alternative investment manager | Finance |
Lilly Research Laboratories
 Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Engages in research and develops medicines | Commercial Services |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital invests in companies located across the globe. The firm targets companies operating in the fields of the biotechnology sector. It provides financing for early and growth stage capital requirements. | Finance |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical and clinical-stage immunotherapy company | Health Technology |
Vaxcyte, Inc.
 Vaxcyte, Inc. BiotechnologyHealth Technology Develops vaccines for infectious diseases | Health Technology |
Mayo Medical School
 Mayo Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Highlight Therapeutics SL
Highlight Therapeutics SL BiotechnologyHealth Technology Develops immuno-oncology treatments for skin cancers | Health Technology |
